Searched for
CONCORD BIOTECH
Two Trades for Today: A maker of forged components for a 7.7% gain, a mid-cap pharma stock for a 6% upmoveOur technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian equities lost momentum after a positive start, with Nifty closing lower and broader markets declining sharply. Investor caution ahea...
- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities ended higher on Tuesday, supported by easing geopolitical tensions and softer crude prices. A sharp drop in India VIX boost...
- Concord Biotech shares jump 8% on USFDA nod for Mycophenolate Mofetil oral suspensionConcord Biotech shares saw a significant jump on Wednesday. This surge followed the company's announcement of receiving approval from the U...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian benchmark indices ended higher after a volatile session, with late buying in heavyweight IT stocks lifting sentiment. Sensex gained ...
- Forget the noise: These 54 smallcap stocks attracted FII buying in March quarterForeign institutional investors are strategically buying into beaten-down smallcap stocks in India, increasing stakes in 54 companies despi...
- Concord Biotech shares tumble 16% after weak Q3 earningsConcord Biotech shares fell 16% to Rs 1,777.7 after the company reported a 2.1% YoY decline in Q3 FY25 net profit to Rs 75.92 crore, despit...
- Concord Biotech shares list at a healthy premium. What should investors do?Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in ...
- Concord Biotech shares list at 21% premium over IPO priceConcord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in ...
- Concord Biotech to list on Friday. Here’s what GMP suggestsAnalysts are of the opinion that a market premium of over 15% on the issue price is justified based on the company's business model, which ...
- Concord Biotech IPO share allotment likely today. Here's how you can check statusOn the allotment date, investors get to know about the number of shares allotted to them as against the bids made. They can check the allot...
- SBFC Finance vs Concord Biotech: Which IPO should you pick?The issue of SBFC Finance comprises fresh equity issue of Rs 600 crore and an offer for sale (OFS) of Rs 425 crore, while Concord Biotech i...
- Concord Biotech IPO subscribed 58% on Day OneThe non-institutional investors (NII) category was subscribed the most at 1.01 times, followed by retail investors at 72%. The category for...
- Concord Biotech IPO opens. Should you subscribe to the issue?Analysts advised investors to subscribe to Concord Biotech IPO given its complex product portfolio, presence in niche space, strong client ...
- Concord Biotech IPO to open on August 4. Here are 10 things to know about the offerThe initial public offering (IPO) of Concord Biotech will open for subscription on August 4. The issue closes on August 8. The company's sh...
- Jhunjhunwala-backed Concord Biotech sets IPO price band at Rs 705-741According to the draft papers, Concord Biotech's IPO is entirely an offer for sale of (OFS) of 2,09,25,652 equity shares by Helix Investmen...
- Concord Biotech files DRHP with Sebi for Rs 2,000-2,500 cr IPOSources told ET that the IPO would be of ₹2000 crore - ₹2500 crore size.The issue with a face value of ₹1 per equity share is a complete of...
- Rare Enterprises, Quadria-backed Concord Biotech files draft IPO papers with SebiAs per an F&S report, Concord Biotech commands a market share of over 20 per cent by volume in 2021 across identified fermentation-based AP...
- Rakesh Jhunjhunwala to give up Concord Biotech stake, eyes Rs 500 crJhunjhunwala is looking to make a quick buck by exiting one of his large investments in the pharma space taking advantage of attractive val...
Load More
